Published date: 30 September 2022
This notice was replaced on 30 September 2022
This notice does not contain the most up-to-date information about this procurement. The most recent notice is:
Awarded contract (published 30 September 2022)
Awarded contract - This means that the contract has been awarded to a supplier.
Contract summary
Industry
Business and management consultancy and related services - 79400000
Location of contract
North East
Value of contract
£30,000
Procurement reference
NCL001-DN621227-59492544
Published date
30 September 2022
Closing date
29 July 2022
Closing time
12pm
Contract start date
18 October 2022
Contract end date
1 April 2023
Contract type
Service contract
Procedure type
Restricted procedure
A two-stage procedure, where the first stage is used to select suppliers, who are then invited to bid in the second stage.
Contract is suitable for SMEs?
Yes
Contract is suitable for VCSEs?
No
Description
1 in 5 adults in the UK suffer from urinary symptoms caused by an overactive bladder (OAB). Symptoms include urgency (a sudden compelling desire to pass urine, which cannot be deferred), increased frequency of voiding (both day and night) and urge incontinence (involuntary leakage accompanied by / immediately preceded by urgency).
The Team wishes to establish a spinout company to produce a Dipstick-style test. Our discovery is currently being developed into a simple-to-use diagnostic tool used for (1) regular screening for OAB in adults, at a GP surgery, pharmacy or nursing home, and (2) to assess the effectiveness of treatments (companion diagnostic) and modifying dosing/treatments accordingly. Accurate and early diagnosis will improve treatment outcomes, eliminating the need for patients to have invasive and high-risk surgery-led second-line treatments necessary for advanced-stage disease.
Currently there is no competition for a non-invasive biomarker-based test, and new product development activity appears to be very limited, suggesting an opportunity for 'first mover advantage' and to establish a standard.
We require a driven executive to take this technology forward and build a compelling proposition for investment. The Executive will need to create a robust business model that is acceptable to the founders, develop and deliver pitch materials for investors and establish collaborative research projects.
The executive appointed should have an appropriate background, ideally with experience of high tech starts ups, securing seed investment and establishing manufacturing facilities.
Award information
Awarded date
6 September 2022
Contract start date
1 October 2022
Contract end date
1 April 2023
Total value of contract
£30,000
This contract was awarded to 1 supplier.
DU Biosciences
Address
London
Greater London
SW19 1JG
United KingdomReference
None
Supplier is SME?
No
Supplier is VCSE?
No
About the buyer
Contact name
Natalie Morton
Address
Newcastle University
Procurement Services, Kingsgate
Newcastle
NE1 7RU
United Kingdom
Telephone
+44 1912086396
Website
Share this notice
All content is available under the
